Alterity Therapeutics (ASX:ATH) has announced that the last patient in its ATH434-201 Phase 2 trial in early-stage multiple system atrophy has completed the study. …
Alterity Therapeutics completes last patient visit in ATH434-201 trial in multiple system atrophy
December 4, 2024 Australian Biotech
Latest Video
New Stories
-
Novo Nordisk backs care for rural health professionals in southern NSW
August 19, 2026 - - Latest News -
Opportunity #3 - finally deliver on the repeated claims of patient-centricity
August 19, 2026 - - Latest News -
Departmental restructure formally splits medicines financing from pharmacy services
August 19, 2026 - - Latest News -
Wesfarmers Health evolves its loyalty program with new Pulse Rewards
August 19, 2026 - -
CSL absorbs loss in reset year as investors back its plasma-led recovery
August 18, 2026 - - Latest News -
Opportunity #2 - AI can democratise HTA and the negotiations must not squander it
August 18, 2026 - - Latest News -
Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - - Latest News